Home > What we do > Medicine & Healthcare > hMedicine > hMedicine Archive

Jules Bordet Institute of Brussels and Hadassah Medical Organization Ratify Agreement to Cooperate






In the presence of Belgium Foreign Minister and Deputy Prime Minister Didier Reynders, the Jules Bordet institute of Brussels and Hadassah Medical Organization today ratified an agreement of collaboration in healthcare, medical education, clinical research and hospital management. Jules Bordet Institute is Belgium's only hospital dealing exclusively with cancer. Joint research with Hadassah has already begun in breast cancer and pediatric oncology, with other fields to follow soon.

Representing Hadassah Medical Organization, HMO Deputy Director responsible for research Yaakov Naparstek said, "In signing business agreements, there's always the feeling that one side is getting more than the other. In contrast, when you sign an agreement to share information, you both enjoy the growing reservoir of knowledge."

"This is a very emotional experience for me," said Foreign Minister Reynders. "There isn't a more meaningful way to cooperate than treating breast cancer and cancer in children. Hadassah is also a bridge for peace. Working together, these two great hospitals are finding ways to add to the betterment of humanity."

Speaking for the Jules Bordet Institute, Professor Maurice Sosnowski, Head of the Department of Anesthesiology and President of Hadassah International Belgium said,
"Joint science and research is proof that the stupidity of hatred contributes nothing to humankind, but cooperation and life-saving medicine will save the world."

The ceremony took place in the Abbell Synagogue, home of the Chagall Windows. The delegation toured the hemo-oncology ward and laboratories for gene therapy.

Read more in The Jerusalem Post

Watch on Shalom TV

Read in The Jerusalem Post

Date: 11/12/2013


More hMedicine Stories




Hadasit, Hadassah’s Technology Transfer Arm, Reviews 2012’s Accomplishments

When the Hadassah University Medical Center’s physicians suggest a solution to a medical problem which can lead to the development of a new medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its feasibility and supports the promotion of those viable ideas with innovation potential. Although 2012 has been “a year full of challenges for the life science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer, Hadasit still signed 125 agreements for clinical trials, all to be done at Hadassah. In addition, Hadasit signed 15 agreements for cooperation and commercialization of technologies that were developed at Hadassah. Click here to read the latest Newsletter from Hadasit >>

   |  Who We Are  |  What We Do  |  Where We Do It  |  Read About It  |  Join Now  |  Donate  |
  |  Login  |  Contact Us  |  Careers  |  Terms & Conditions  |  
Copyright ©2014 Hadassah is a registered trademark of Hadassah, the Women's Zionist Organization of America